McKESSON CORPORATION (MCK) FY2026 YTD Q3 P&L / Income Statement

McKESSON CORPORATION (MCK) FY2026 YTD Q3 P&L / Income Statement

Income statement for 2025-04-01 through 2025-12-31. View: Business segment. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenues

307,135,000,000 US dollars

Cost of sales

296,629,000,000 US dollars

Gross profit

10,506,000,000 US dollars

Total operating expenses

6,444,000,000 US dollars

Operating income

4,062,000,000 US dollars

Other income (expense), net (calculated)

14,000,000 US dollars

Income before income taxes

4,076,000,000 US dollars

Income tax expense

832,000,000 US dollars

Net income

3,244,000,000 US dollars

North American Pharmaceutical

257,532,000,000 US dollars

Oncology & Multispecialty

35,712,000,000 US dollars

Prescription Technology Solutions

4,310,000,000 US dollars

Medical-Surgical Solutions

8,639,000,000 US dollars

Selling, distribution, general, and administrative expenses

6,300,000,000 US dollars

Claims and litigation charges, net

negative 2,000,000 US dollars

Restructuring, impairment, and related charges, net

146,000,000 US dollars

Revenue before reconciliation (calculated)

306,193,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.

Other

942,000,000 US dollars. Reported reconciliation to consolidated revenue.

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.
• Of which attributable to McKESSON CORPORATION: $3.08 B; to noncontrolling interests: $164.00 M.